Sarah A. Reda

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d2a5b100-504e-11ef-931e-8373c6b518fb.jpg

First Name

Sarah

Last Name

Reda

NPI

1003304510

Faculty ID

17794

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

186405

Visit Type ID

2499

Is Open Scheduling

On

Rimon Golovey

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/a64720b0-f4e9-11ed-b68f-a56b34798745.jpg

First Name

Rimon

Last Name

Golovey

NPI

1225666993

Faculty ID

17585

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

123893

Visit Type ID

2541

Is Open Scheduling

On

Sriram Machineni

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c68653a0-bec9-11ee-aa99-759018b444d6.jpg

First Name

Sriram

Last Name

Machineni

NPI

1750350666

Faculty ID

17510

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni obtained his medical degree from the All India Institute of Medical Sciences in New Delhi, followed by a residency in internal medicine at the State University of New York at &nbsp;Buffalo. He served as chief resident and primary care teaching physician at Buffalo General Hospital. He subsequently completed a clinical and research fellowship in obesity medicine and metabolism at Massachusetts General Hospital/ Harvard Medical School and stayed on as an instructor. Dr. Machineni studied energy balance and body fat regulation in animal models allowing the interpretation of clinical research findings and phenotypes in the context of physiology.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni moved to the University of North Carolina at Chapel Hill (UNC) to start a clinical obesity program for treatment, education, and pharmaceutical clinical obesity trials. During his term at UNC, he helped create an obesity primary care network in central North Carolina. He was recruited to Montefiore Medical Center to develop a new medical obesity program.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">The Fleischer Institute Medical Weight Center at Montefiore Einstein, founded by Dr. Machineni, is designed to support clinical, educational, and research endeavors in the field of obesity medicine. The program leverages individual variations in response to treatments and uses multiple modalities for weight reduction to treat the comorbidities of obesity and improve quality of life. Special programs are available for individuals who need to lose weight to quality for medical and surgical procedures. The Medical Weight Center works closely with the Montefiore bariatric surgery program to offer a broad spectrum of treatment modalities.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">Dr. Machineni has clinical expertise in the m</span><span style="font-family: Calibri, sans-serif; font-size: 12pt;">ultidisciplinary management of obesity, anti-obesity medications, and post-bariatric medical complications, including nutritional deficiencies, hypoglycemia, weight regain, malabsorption, and diarrhea. He</span><span style="font-family: Calibri, sans-serif;">&nbsp;is among a handful of physicians in the New York area with Castle Connolly Top Doctors designation in obesity medicine.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p>1: Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H,Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; <strong>SURMOUNT-2 investigators</strong>.Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi:10.1016/S0140-6736(23)01200-X. Epub ahead of print. PMID: 37385275.</p>
<p>2: Pagidipati NJ, Mulder H, Chiswell K, Lampron Z, Jones WS, <strong>Machineni S</strong>,Waitman LR, Mongraw-Chaffin M, Waterman F, Kumar N, Ramasamy A, Smolarz G,Peterson ED, O'Brien E. Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity. PrevMed. 2023 May;170:107496. doi:10.1016/j.ypmed.2023.107496. Epub 2023 Mar 29.PMID: 36997096.</p>
<p>3: Ro SJ, Lackey AR, Aymes SE, McCauley JL, Davis TC, Wang R, Stanley W, Ratner SP, <strong>Machineni S</strong>, Fiscus LC. Impact of a Community-Based Weight Management Program in a North Carolina Health Care System. Fam Med. 2023 Mar;55(3):189-194.doi: 10.22454/FamMed.2023.603918. Epub 2023 Jan 31. PMID: 36888674.</p>
<p>4: Aronne LJ, Bramblette S, Ingelfinger JR, Jastreboff AM, <strong>Machineni S,</strong> Massie N, Rosen CJ. When Weight Impacts Health. N Engl J Med. 2023 Jan 12;388(2):e2. doi: 10.1056/NEJMp2215794. PMID: 36630621.</p>
<p>5: Aronne LJ, Bramblette S, Huett-Garcia A, Ingelfinger JR, Jastreboff AM, <strong>Machineni S</strong>, Massie N, Rosen CJ. Weight and Health - Pathophysiology and&nbsp;Therapies. N Engl J Med. 2022 Dec 15;387(24):e62. doi: 10.1056/NEJMp2214423. PMID: 36516089.</p>
<p>6: le Roux CW, Zhang S, Aronne LJ, Kushner RF, Chao AM, <strong>Machineni S</strong>, Dunn J, Chigutsa FB, Ahmad NN, Bunck MC. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2023 Jan;31(1):96-110. doi: 10.1002/oby.23612. Epub 2022 Dec 7. PMID: 36478180; PMCID: PMC10107501.</p>
<p>7: Bionic Pancreas Research Group; Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K,Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB,Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, Forlenza G, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, <strong>Machineni S</strong>, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172. doi: 10.1056/NEJMoa2205225. PMID: 36170500; PMCID: PMC10028490.</p>
<p>8: Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, <strong>Machineni S</strong>, Varbo A,Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism andGlycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg AmongParticipants With Prediabetes in the STEP Program. Diabetes Care. 2022 Oct1;45(10):2396-2405. doi: 10.2337/dc21-1785. PMID: 35724304; PMCID: PMC9862484.</p>
<p>9: Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A,Zhang S, Liu B, Bunck MC, Stefanski A; <strong>SURMOUNT-1 Investigators</strong>. TirzepatideOnce Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.</p>
<p>10: Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, Buse JB, Valcarce C;<strong>SimpliciT1 research group</strong>. The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. Diabetes Care. 2021 Apr;44(4):960-968. doi:10.2337/dc20-2684. Epub 2021 Feb 23. PMID:33622669; PMCID: PMC7985421.</p>
<p>11: Melanie Davies, Louise F&aelig;rch, Ole K Jeppesen, Arash Pakseresht, Sue D Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A Wadden, Ildiko Lingvay; <strong>STEP 2 Study Group</strong>.&nbsp; Semaglutide 2&middot;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. PMID: 33667417.</p>
<p>12: Rosman L, Armbruster T, Kyazimzade S, Tugaoen Z, Mazzella AJ, Deyo Z, Walker J, <strong>Machineni S,</strong> Gehi A. Effect of a virtual self-management intervention for atrial fibrillation during the outbreak of COVID-19. Pacing Clin Electrophysiol. 2021 Mar;44(3):451-461. doi: 10.1111/pace.14188. Epub 2021 Feb 17. PMID: 33565642; PMCID: PMC8014277.</p>
<p>13: Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; <strong>STEP 3 Investigators.</strong> Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Feb 24. PMID: 33625476; PMCID: PMC7905697.</p>
<p>14: Jensen SM, Thompson RE, <strong>Machineni S,</strong> Overby DW, Farrell TM. Refractory Hypocalcemia Following Stomach Intestinal Pylorus-Sparing Bariatric Surgery and Thyroidectomy: Successful Management With Creation of a Proximal Roux-en-Y Gastric Bypass. Am Surg. 2021 Apr;87(4):576-580. doi: 10.1177/0003134820952427. Epub 2020 Oct 30. PMID: 33125276.</p>
<p>&nbsp;</p>
<p>15: Kushner RF, Batsis JA, Butsch WS, Davis N, Golden A, Halperin F, Kidambi S, <strong>Machineni S,</strong> Novick M, Port A, Rubino DM, Saunders KH, Shapiro Manning L, Soleymani T, Kahan S. Weight History in Clinical Practice: The State of the Science and Future Directions. Obesity (Silver Spring). 2020 Jan;28(1):9-17. doi: 10.1002/oby.22642. PMID: 31858735.</p>
<p>16: Kushner RF, Butsch WS, Kahan S, <strong>Machineni S,</strong> Cook S, Aronne LJ. Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested? Teach Learn Med. 2017 Apr-Jun;29(2):123-128. doi:10.1080/10401334.2016.1250641. Epub 2016 Dec 29. PMID: 28033472.</p>
<p>17: Carmody JS, Ahmad NN, <strong>Machineni S,</strong> Lajoie S, Kaplan LM. Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice. Endocrinology. 2015 Sep;156(9):3183-91. doi: 10.1210/en.2015-1226. Epub 2015 Jun 11. PMID: 26066076; PMCID: PMC4541621.</p>
<p>18: Liou AP, Paziuk M, Luevano JM Jr, <strong>Machineni S,</strong> Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013 Mar 27;5(178):178ra41. doi:10.1126/scitranslmed.3005687. PMID: 23536013; PMCID: PMC3652229.</p>
<p>19: Bose M, Teixeira J, Olivan B, Bawa B, Arias S, <strong>Machineni S,</strong> Pi-Sunyer FX, Scherer PE, Laferr&egrave;re B. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010 Mar;2(1):47-55. doi: 10.1111/j.1753-0407.2009.00064.x. PMID: 20676394; PMCID: PMC2910618.</p>
<p>20: Bose M, <strong>Machineni S,</strong> Oliv&aacute;n B, Teixeira J, McGinty JJ, Bawa B, Koshy N, Colarusso A, Laferr&egrave;re B. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring). 2010 Jun;18(6):1085-91. doi: 10.1038/oby.2009.473. Epub 2010 Jan 7.PMID: 20057364; PMCID: PMC2877144.</p>

EMR ID

179058

Is Open Scheduling

Off

Michele H. Mokrzycki

https://assets.montefioreeinstein.org/profiles/images/physphoto/Mokrzycki_Michele_MD-2.jpg

First Name

Michele

Last Name

Mokrzycki

NPI

1215048822

Faculty ID

4647

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Mokrzycki&nbsp;is a graduate of&nbsp;Boston College (B.S., 1983),&nbsp;and the University of Vermont College of Medicine (M.D., 1987) and received a&nbsp;Masters&nbsp;of Science&nbsp;in Clinical Research from the Albert Einstein College of Medicine (M.S. 2000). She&nbsp;completed&nbsp;both an&nbsp;Internal&nbsp;Medicine Residency and Clinical Nephrology Fellowship at the University&nbsp;of&nbsp;Connecticut Health Science Center in Farmington, CT. &nbsp;Dr Mokrzycki has been on faculty at the Albert Einstein College of Medicine since 1992, where she is a Professor of Medicine in the Division of Nephrology. &nbsp;She is a full time clinical nephrologist at the Montefiore Medical Center, Moses Campus.</p>
<p>Dr Mokrzycki's&nbsp;research interests have focused primarily on hemodialysis vascular access related complications, specifically,&nbsp;complications associated with tunneled catheter use such as infection/bacteremia/inflammation and dysfunction/thrombosis. &nbsp;</p>
<p>She is the recipient of a grant from the AETNA Foundation to study the effect of a multidisciplinary team approach to improve outcomes associated with catheter bacteremia in hemodialysis patients. &nbsp;</p>
<p>Dr Mokrzycki&nbsp;served on the Program Committee Member for the National Kidney Foundation (NKF)&nbsp;for 2 years, and on Faculty for the Therapeutic Apheresis Academy (TAA)&nbsp;for&nbsp;5 years, which is&nbsp;held annually at the University of Virginia College of Medicine. She has been an invited speaker and/or chaired sessions&nbsp;at the American Society of Nephrology (ASN),&nbsp;National Kidney Foundation (NKF), the Vascular Access Society (VAS), Hemodialysis University (HDU), Annual Dialysis Conference (ADC), the&nbsp;American Society of Diagnostic and Interventional Nephrology (ASDIN), and the VEITH symposium.</p>
<p>Dr Mokrzycki served on the Catheter Endpoints Workgroup of the Kidney Health Initiative (KHI), formed by the American Society of Nephrology,the FDA and other stakeholders in End Stage Kidney Disease Innovation. &nbsp;Dr Mokrzycki currently serves as the Chair of the Vascular Accesss Outcomes Workgroup, a subgroup of the Nephrologists Transforming Dialysis Safety Initiative (NTDS), which is a collaboration between the American Society of Nephrology and the Centers for Disease Control.&nbsp;</p>
<p>&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Dr. Mokrzycki is board certified in Nephrology and is a Fellow of the American Society of Nephrology. Clinical interests include Glomerular Diseases, Acute and Chronic Kidney Diseases, Hypertension, Kidney Stones, Renal Cystic Diseases, Dialysis, and Vascular Access for Hemodialysis.</p>

Research Focus

<p>Dr. Mokrzycki completed a Masters Program in Clinical Research at the Albert Einstein College of Medicine. The author of over 50 peer-reviewed publications, Dr. Mokrzycki&rsquo;s research focuses on reducing hemodialysis vascular access infectious and thrombotic complications.</p>

Elsevier Profile

Selected Publications

<ol>
<li><strong>Mokrzycki MH</strong>, Yamase H, Kohn OF.&nbsp; Renal malacoplakia with papillary necrosis and renal failure. Am J Kidney Dis 19:587-91, 1992.</li>
<li><strong>Mokrzycki MH</strong>, Kaplan AA.&nbsp; Therapeutic Plasma Exchange: Complications and management.&nbsp; Am J Kidney Dis 23:817-27, 1994.</li>
<li><strong>Mokrzycki MH</strong>, Rickles F, Kaplan AA, Kohn OF.&nbsp; Thrombotic thrombocytopenic purpura in pregnancy: Successful treatment with plasma exchange.&nbsp; Blood Purif 13:271-82, 1995.</li>
<li>Posner L, <strong>Mokrzycki MH</strong>. Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use.&nbsp; Am J Nephrol 16:339-43,1996.</li>
<li>Kerr A, Spector J, <strong>Mokrzycki MH</strong>, Blau S, Simon R.&nbsp; V asodilator provocation of occult urinar y tract hemorrhage. J Trauma 40:152-4, 1996.</li>
<li><strong>Mokrzycki MH</strong><span style="text-decoration: underline;">,</span> Kaplan AA.&nbsp; Protein losses in continuous renal replacement therapies. J Am Soc Nephrol 7:1-5, 1996.</li>
<li><strong>Mokrzycki MH</strong><span style="text-decoration: underline;">,</span> Harris C, May H, Laut J, Palmisano J.&nbsp; Lactic acidosis associated with stavudine (d4T): Report of 5 cases. Clin Inf Dis 30:198-200, 2000.</li>
<li><strong>Mokrzycki MH</strong>, Schroppel B, von Gersdorff G, Rush H, Zdunek M, Feingold R.&nbsp; Tunneled cuffed catheter associated infections in hemodialysis patients seropositive for the human immunodeficiency virus.&nbsp; J Am Soc Nephrol 11:2122-2127, 2000.</li>
<li>Barisoni L, <strong>Mokrzycki MH</strong>, Sablay L, Nagata M, Yamase H, Mundel P.&nbsp; Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies.&nbsp; Kidney Int 58:137-143, 2000.</li>
<li>Zdunek MP, Mitra A, <strong>Mokrzycki MH</strong>.&nbsp; Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: Timing is important for maximizing clearance.&nbsp; Am J Kidney Dis 36:177-183, 2000.</li>
<li>Solomon N, <strong>Mokrzycki MH</strong>.&nbsp; Levofloxacin-associated allergic interstitial nephritis.&nbsp; Clin Nephrol 54:356, 2000.</li>
<li><strong>Mokrzycki MH</strong>, Jean-Jerome K, Rush H, Zdunek MP, Rosenberg SO.&nbsp; A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 59:1935-1942, 2001.</li>
<li>Swiatecka-Urban A, <strong>Mokrzycki MH</strong>, Kaskel F, Da Silva F, Denamur E.&nbsp; Novel WT1 mutation (C388Y) in a female child with Denys-Drash syndrome.&nbsp;&nbsp; Pediatr Nephrol 16:627-630, 2001.</li>
<li><strong>Mokrzycki MH,</strong> Singhal A.&nbsp; Cost-Effectiveness of Three Strategies of Managing Tunneled-Cuffed Hemodialysis Catheters (TCC) in Clinically Mild or Asymptomatic Bacteremias.&nbsp; Nephrol Dial Transpl 17(12): 2196-203, 2002.</li>
<li>Negulescu O, Coco M, Croll J, <strong>Mokrzycki MH</strong>. Large atrial thrombus formation associated with tunneled cuffed hemodialysis catheters. Clin Nephrol 59(1):40-6, 2003.</li>
<li>Golestaneh L, Laut J, Rosenberg S, Zhang M, <strong>Mokrzycki MH</strong>.&nbsp; Favourable outcomes in episodes of Pseudomonas bacteremia when associated with tunneled cuffed catheters (TCC) in chronic hemodialysis patients.&nbsp; Nephrol Dial Transplant. May;21(5):1328-33,2006.</li>
<li><strong>Mokrzycki MH</strong>, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO.&nbsp; Tunneled Hemodialysis Catheter Bacteremia: Risk factors for bacteremia recurrence, infectious complications and mortality. Nephrol Dial Transplant. 21(4):1024-31,2006.</li>
<li><strong>Mokrzycki MH</strong>, Zhang M, Golestaneh L, Laut J, Rosenberg SO.A randomized controlled trial comparing two management models for the treatment of tunneled cuffed catheter (TCC) bacteremia: A collaborative team model versus usual physician-managed care. Am J Kidney Dis 48(4):587-95, 2006.</li>
<li>McKenzie LM, Hendrickson, SL, Briggs WA, Dart RA, Korbet SM, <strong>Mokrzycki MH</strong>, Kimmel PL, Ahuja TS, Berns JS, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Cho M, Zhou YC, Binns-Roemer E, Kirk GD, Kopp JB, Winkler CA.&nbsp; NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol 18(11): 2987-95, 2007</li>
<li><strong>Mokrzycki MH.</strong>&nbsp; Use of prophylactic topical or intraluminal antibiotics for hemodialysis catheters. Nat Clin Pract Nephrol 4(9):478-9, 2008.</li>
<li>Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, <strong>Mokrzycki MH</strong>, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 40 (10):1175-84, 2008.</li>
<li>Sachdeva M, Bitzer M, <strong>Mokrzycki MH</strong>. Vascular access type and changes in inflammatory markers in incident dialysis patients: a pilot study.&nbsp; J Vascular Access 10(3):174-179, 2009.</li>
<li>Golestaneh L, Gofran A, <strong>Mokrzycki MH</strong>, Chen JL.&nbsp; Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing.&nbsp; Clin Neph 72 (4):286-291.</li>
<li>Okafor C, Ward DM, <strong>Mokrzycki MH,</strong> Weinstein R, Clark P, Balogun RA.&nbsp; Introduciton and overview of therapeutic apheresis.&nbsp; J Clin Apheresis, 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>.&nbsp; Advances in Hemodialysis Catheter-related Infection.&nbsp; U.S. Nephrol, 2010.</li>
<li><strong>Mokrzycki MH</strong>, Lok CE. Traditional and nontraditional strategies to optimize catheter function: <em>Go with more flow.</em> Kidney Int, 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>.&nbsp; Update 2010: Catheter-related Infection in Hemodialysis Patients. Kidney Int. 2010.</li>
<li>Lok CE, <strong>Mokrzycki MH</strong>.&nbsp; Prevention and management of catheter-related infection in hemodialysis patients.&nbsp; Kidney Int. 2010;79(6):587-98.</li>
<li><strong>Mokrzycki MH</strong>, Balogun RA.&nbsp; Therapeutic Apheresis: a review of complications and recommendations for prevention and management.&nbsp; J Clin Apher 2011:26(5):243-8.</li>
<li>Lee T, <strong>Mokrzycki MH</strong>, Moist L, Maya I, Vazquez M, Lok CE; North American Vascular Access Consortium. Standardized definitions for hemodialysis vascular access. Semin Dial 2011;24(5):515-24.</li>
<li>Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, <strong>Mokrzycki MH</strong>, Kimmel PL, Limous S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollack M, Winkler CA.&nbsp; APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-Associated nephropathy. J Am Soc Nephrol 2011;22(11):2129-37.</li>
<li>Sachdeva M, Hung A, Kovalchuk O, Bitzer M, <strong>Mokrzycki MH</strong>. The initial vascular access type contributes to inflammation in incident hemodialysis patients. Int J Nephrol Volume 2012; (2012) Article ID: 917465.</li>
<li>Lee T, Lok C, Vazquez M, Moist L, Maya I, <strong>Mokrzycki M</strong>.&nbsp; Minimizing hemodialysis catheter dysfunction: An ounce of prevention.&nbsp; Int J Nephrol; Volume 2012 (2012), Article ID: 170857.</li>
<li>Golestaneh L, <strong>Mokrzycki MH</strong>. Vascular Access in Therapeutic Apheresis: Update 2013.&nbsp; J Clin Apheresis. 2013: 28(1):64-72.</li>
<li>Nica A, Lok CE, Harris J, Lee TC, <strong>Mokrzycki MH</strong>, Maya ID, Vazquez MA, Xi W, Moist LM; From the North American Vascular Access Consortium (NAVAC). Understanding Surgical Preference and Practice in Hemodialysis Vascular Access creation. Semin Dial. 2013:26(4):520-526.</li>
<li>Bhatt DL, Kandzari DE, O&rsquo;Neill WW, D&rsquo;Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014;370 (15):1393-1401.</li>
<li><strong>Mokrzycki MH</strong>, Lok CE. Optimizing central venous catheter primary prevention trials in hemodialysis patients. Am. J.Kidney Dis. 2015;66(6):939-941.</li>
<li>Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson P, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova , Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, <strong>Mokrzycki MH</strong>, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M. Complete remission in the nephrotic syndrome study network. Clin J Am Soc Nephrol. 2016;11 (1):81-89.</li>
<li>Johns, TS, <strong>Mokrzycki MH</strong>. Optimal approach for the diagnosis of hemodialysis catheter-related bacteremia. Clin J Am Soc Nephrol 2016; 11.</li>
<li>Liang E, Rodriguez M, Mueller M, Abramowitz MK, <strong>Mokrzycki&nbsp; MH</strong>. Outcomes Associated with a Heparin-Free Hemodialysis Protocol and Review of the Literature. J. Clin. Nephrol. Renal Care. 2016, 2(1): 10-16.</li>
<li>Allon M, Brouwer-Maier DJ, Abreo K, Baskin KM, Bregel K, Chand D,&nbsp; Easom A, Mermel L, <strong>Mokrzycki MH</strong>, Patel PR, Roy-Chaudhury P, Shenoy S, Valentini RP, Wasse H.&nbsp; Moving Points in Nephrology: Recommended Clinical Trial Endpoints for Hemodialysis Catheters. Clin J Am Soc Nephrol. 2017</li>
<li>&nbsp;Golestaneh L, <strong>Mokrzycki MH</strong>. Prevention of Hemodialysis Catheters Infections: Ointments, Dressings, Locks and Catheter Hub Devices. Hemodial Int. Nov 2018</li>
<li>Der E, Suryawanshi H, Morozov P, Kustagi M, Goilav B, Ranabathou S, Izmirly P, Clancy R, Belmont HM, Koenigsberg M, <strong>Mokrzycki M</strong>, Rominieki H, Graham JA, Rocca JP, Bornkamp N, Jordan N, Schulte E, Wu M, Pullman J, Slowikowski K, Raychaudhuri S, Guthridge J, James J, Buyon J, Tuschl T, Putterman C; Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Consortium. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol. 2019 Jul;20(7):915-927</li>
<li>Fisher M, Golestaneh L, Allon M, <span style="font-family: 'Times New Roman', serif; font-size: 12pt;">&nbsp;</span><span style="font-family: 'Times New Roman', serif; font-size: 12pt;">Abreo K, </span><strong style="font-family: 'Times New Roman', serif; font-size: 12pt;">Mokrzycki MH.&nbsp;</strong>Preventing Central Vein Catheter Associated Bloodstream Infections in Hemodialysis: Review of Current Evidence-Based Strategies and Novel Therapies. <span style="font-size: 12pt; font-family: 'Times New Roman', serif;">Clin J Am Soc Nephrol 2020;15:132-151</span></li>
<li><span style="font-size: 12.0pt; font-family: 'Times New Roman','serif'; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Vachharajani T , Wong L, Niyyar VD, Abreo KD, <strong>Mokrzycki MH</strong>, for the Vascular Access Workgroup of the Nephrologists Transforming Dialysis Safety Initiative of the American Society of Nephrology. Buttonhole cannulation of arteriovenous fistulas in the United States. Kidney360. 2020 </span></li>
<li><strong style="text-indent: -0.25in; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-size: 12pt;">Mokrzycki MH</span></strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;"> and Coco M. Management of hemodialysis patients with suspected or confirmed COVID-19 infection: perspective of two nephrologists in the United States. Kidney360. 2020:1(4);273-278.</span></li>
<li><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;</span><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">Fisher M, Yunes M, <strong>Mokrzycki MH</strong>, Golestaneh L, Alahiri E, Coco M. &ldquo;Chronic Hemodialysis Patients Hospitalized with COVID-19 &ndash; Short-term Outcomes in Bronx, New York&rdquo;. Kidney360 June 2020</span>1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></li>
<li><strong style="text-indent: -0.25in;"><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif;">Mokrzycki MH</span></strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">, Leigh KA, Kliger AS, Niyyar VD, Bren Asp V, Golestaneh L, Taylor Q, Novosad SA. Implementation of an Electronic Catheter Checklist in Outpatient Hemodialysis Facilities: Results of a Pilot Quality Improvement Project. Kidney360&nbsp; April 2021, 2(4) 684-694</span>
<p class="MsoListParagraph" style="text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;">&nbsp;</p>
</li>
</ol>
<p><em><strong><span style="text-indent: -0.25in; font-size: 12pt; font-family: 'Times New Roman', serif;">Book Chapter</span></strong></em></p>
<p class="MsoListParagraph" style="text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';">&nbsp; &nbsp; &nbsp;</span></span></span><span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;">Fisher M, <strong style="mso-bidi-font-weight: normal;">Mokrzycki MH.</strong> Infectious complications in vascular access. Handbook of Dialysis. Nissenson: Handbook of Dialysis Therapy, 6e.</span> <span style="font-size: 12.0pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;">Elsevir (In press, 2021)</span></p>

EMR ID

3774

Biography

<p>Michele H. Mokrzycki, MD, MS, is an attending nephrologist and Professor, Medicine at Montefiore Einstein. Dr. Mokrzycki&rsquo;s clinical interests include glomerular diseases, acute and chronic kidney diseases, hypertension, kidney stones, renal cystic diseases, dialysis and vascular access for hemodialysis.</p><p>After earning her Bachelor of Science from Boston College in 1983, Dr. Morkrzycki pursued her Doctor of Medicine at University of Vermont College of Medicine, earning the degree in 1987. She performed her postdoctoral training at University of Connecticut Health Center, completing her residency in internal medicine in 1990 and her fellowship in clinical nephrology in 1992. Dr. Mokrzycki later pursued additional education, completing her Master of Science in clinical research at Einstein in 2000.</p><p>Author of over 50 peer-reviewed publications, Dr. Mokrzycki&rsquo;s research focuses on reducing hemodialysis vascular access infectious and thrombotic complications. She is on the editorial board for <em>Kidney360</em>, and is an invited reviewer for several publications including the <em>Journal of the American Society of Nephrology, Hemodialysis International</em> and the <em>Journal of Vascular Access.</em></p><p>Dr. Mokrzycki is board certified in Nephrology. She is a Fellow of the American Society of Nephrology and a member of several professional societies including the National Kidney Foundation, New York Society of Nephrology and the North American Vascular Access Consortium. In 2020, she was recognized as Reviewer of the Year by <em>Kidney360</em>.</p>

Is Open Scheduling

On

Luigi Di Biase

https://assets.montefioreeinstein.org/profiles/images/physphoto/DiBiase_Luigi_MD_PhD_420x504.jpg

First Name

Luigi

Last Name

Di Biase

NPI

1891045837

Faculty ID

13629

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<blockquote>
<p class="lessPadding">Dr. Luigi Di Biase is Section Head of Electrophysiology, Director of Arrhythmia Services, and Professor of Medicine (Cardiology) at Einstein/Montefiore. In addition, he serves as Senior Researcher at the Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Austin, Texas.</p>
<p>Improving patient care is the heart of Dr. Di Biase's mission. He believes that this is possible through dedicated clinical practice associated to cutting-edge clinical research. Dr. Di Biase's research focuses on cardiology and electrophysiology with specific emphasis on catheter ablation of atrial fibrillation and ventricular arrhythmias performed either manually or with robotic catheter navigation. Additionally, his research focuses on heart failure, particularly cases treated with cardiac resynchronization therapy devices.</p>
<p>Dr. Di Biase, MD, PhD, FACC, FHRS, is a 2000 graduate (summa cum laude) of the medical school and a 2004 graduate (summa cum laude) of the cardiology residency program at the University of Bari, Bari, Italy. In 2006, he completed a second-level master degree in Electrophysiology and Pacing (summa cum laude) at the University of Insubria, Varese, Italy.</p>
<p>In 2007, Dr. Di Biase received a grant from the Italian National Society of Cardiology to pursue a research fellowship under the supervision of Dr. Andrea Natale at the Miller Family Heart &amp; Vascular Institute at the Cleveland Clinic, Cleveland, Ohio. The following year, he accepted a position in cardiac electrophysiology at the University of Texas Medical School Branch in Galveston, Texas, where he continued to focus on his research projects at St. David's Medical Center under the leadership of Dr. Natale.</p>
<p>Dr. Di Biase was appointed Assistant Professor in 2007 at the University of Foggia, Italy, where he completed the PhD program in cardiovascular physiopathology in November 2010.</p>
<p>In 2009, Dr. Di Biase was appointed Adjunct Assistant Professor at the University of Texas at Austin, where he was promoted to Adjunct Associate Professor in 2012, the same year he joined Albert Einstein College of Medicine and Montefiore Medical Center&nbsp;with the title of Associate Professor, Department of Medicine (Cardiology).</p>
<p>In September 2014 Dr. Di Biase was appointed Section Head of Electrophysiology and Director of Arrhythmia Services at Einstein/Montefiore, while continuing to serve as Senior Researcher at the Texas Cardiac Arrhythmia Institute at St. David's Medical Center.&nbsp;</p>
<p>Subsequently Dr. Di Biase was promoted to the rank of Professor of Medicine, Department of Medicine (Cardiology).</p>
<p>Dr. Di Biase is the author of more than 450 publications in indexed journals, about 500 abstracts, and 18 electrophysiology book chapters. He has presented at numerous national and international conferences as an invited speaker.</p>
<p class="lessPadding">Dr. Di Biase is a member of the Italian Federation of Cardiology and Electrophysiology (FIC-AIAC), the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA), the American College of Cardiology (ACC), the American Heart Association (AHA), and a Fellow of the Heart Rhythm Society (FHRS), and the American College of Cardiology (FACC). He is also an honorary member of the Korean Society of Cardiology.</p>
<p class="lessPadding">Dr Di Biase serves as reviewer of major electrophysiology and cardiology journals, and as an editorial board member of&nbsp;<em>Heart Rhythm Journal</em>,&nbsp;<em>Heart Rhythm Journal Case Report</em>, and&nbsp;<em>Journal of Cardiovascular Medicine</em>. He is Associate Editor for&nbsp;<em>Journal Interventional Cardiac Electrophysiology (JICE)</em>&nbsp;and Associate Section Editor for&nbsp;<em>Pacing and Clinical Electrophysiology (PACE)</em>.</p>
<p class="lessPadding">Dr. Di Biase sees patients on both Einstein and Moses campuses of Montefiore Medical Center and at the Hutch Metro Center at Water Place.</p>
<p class="lessPadding"><strong><br /></strong></p>
<p class="lessPadding"><strong>More Information About Dr. Luigi Di Biase</strong></p>
<p class="lessPadding"><a href="http://www.einstein.yu.edu/departments/medicine/divisions/cardiology/ne… is More in Ablation for Ventricular Arrhythmia</a></p>
<p><a href="http://www.einstein.yu.edu/departments/medicine/divisions/cardiology/ne…; target="blank">Can the shape of the left atrial appendage affect stroke risk?</a></p>
<p><a href="http://www.einstein.yu.edu/departments/medicine/divisions/cardiology/ne…; target="blank">Continuous Warfarin Therapy for Patients Undergoing Catheter Ablation</a></p>
</blockquote>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Improving patient care is the heart of Dr. Di Biase's mission. He believes this is possible through dedicated clinical practice associated to cutting-edge clinical research.</p>

Research Focus

<p>Dr. Di Biase's research focuses on cardiology and electrophysiology with specific emphasis on catheter ablation of atrial fibrillation and ventricular arrhythmias performed either manually or with robotic catheter navigation. Additionally, his research focuses on heart failure, particularly cases treated with cardiac resynchronization therapy devices.</p>

Elsevier Profile

Selected Publications

<ol>
<li>Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Mohanty S, Horton R, Gallinghouse GJ, Bailey SM, Zagrodzky JD, Santangeli P, Hao S, Hongo R, Beheiry S, Themistoclakis S, Bonso A, Rossillo A, Corrado A, Raviele A, Al-Ahmad A, Wang P, Cummings JE, Schweikert RA, Pelargonio G, Dello Russo A, Casella M, Santarelli P, Lewis WR, Natale A. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2010;122:109-18. PMID 20606120.</li>
<li>Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Lakkireddy D, Verma A, Khaykin Y, Hongo R, Hao S, Beheiry S, Pelargonio G, Della Russo A, Casella M, Santarelli P, Santangeli P, Wang P, Al-Ahmad A, Patel D, Themistoclakis S, Bonso A, Rossillo A, Corrado A, Raviele A, Cummings JE, Schweikert RA, Lewis WR, Natale A. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation. 2010;121:2550-6. Epub 2010 Jun 1. PMID: 20516376.</li>
<li>Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi CS, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Casella M, Fassini G, Tondo C, Schweikert RA, Natale A. Periprocedural Stroke and Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management: Results From the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Randomized Trial. Circulation. 2014 ;129:2638-44.</li>
<li>Di Biase L, Santangeli P, Burkhardt D, Bai R, Mohanty P, Carbucicchio C, Dello Russo A, Casella M, Mohanty S, Pump A, et al. Endo-epicardial homogenization of the scar versus limited substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol. 2012; 60:132-141.</li>
<li>Di Biase L, Santangeli P, Anselmino M, Mohanty P, Salvetti I, Gili S, Horton R, Sanchez JE, Bai R, Mohanty S, Pump A, Mauricio Cereceda Brantes, Gallinghouse GJ, Burkhardt JD, Federico Cesarani, Scaglione M, Natale A, Gaita F. Does the left atrial appendage morphology correlate with the risk of stroke in patients with AF? Result from a multicenter study. J Am Coll Cardiol. 2012;60:531-8.</li>
</ol>

EMR ID

5640

Biography

<p>Luigi Di Biase, MD, PhD, FACC, FHRS, is Section Head of Electrophysiology and Director of Arrhythmia Services at Montefiore as well as Professor of Medicine (Cardiology) at our&nbsp;<a href="http://www.einstein.yu.edu/faculty/13629/luigi-di-biase/&quot; target="_blank" rel="noopener noreferrer">Albert Einstein College of Medicine</a>.</p><p>Dr. Di Biase attended University of Bari in Bari, Italy, graduating&nbsp;from its medical school in 2000 and Cardiology residency program in 2004. In 2006, he completed a second-level master&rsquo;s degree in Electrophysiology and Pacing at the University of Insubria, in Varese, Italy.</p><p>In 2007, Dr. Di Biase received a grant from the Italian National Society of Cardiology to pursue a research fellowship at the Miller Family Heart &amp; Vascular Institute at the Cleveland Clinic. Dr. Di Biase completed the PhD program in cardiovascular physiopathology at the University of Foggia, Italy, in 2010.</p><p>Dr. Di Biase's research focuses on cardiology and electrophysiology, with an emphasis on catheter ablation of atrial fibrillation and ventricular arrhythmias performed either manually or with robotic catheter navigation. His research focuses on heart failure, particularly in cases treated with cardiac resynchronization therapy devices.</p><p>Dr. Di Biase is the author of more than 450 publications in indexed journals, roughly 500 abstracts, and 16 electrophysiology book chapters. He has presented as an invited speaker at numerous national and international conferences and serves as Associate Editor for Pacing and Clinical Electrophysiology (PACE) as well as&nbsp;the Journal of Interventional Cardiac Electrophysiology (JICE). He is the Editorial Team Lead for the American College of Cardiology in the field of Electrophysiology. He co-authored the 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation, which is globally referenced for best-practices in cardiac ablation.</p><p>Dr. Di Biase is the highest published Electrophysiology faculty member and is also one of the world&rsquo;s most published physicians on the topic of cardiac electrophysiology and atrial fibrillation.<br /><br /> Dr. Di Biase is a member of the Italian Federation of Cardiology and Electrophysiology (FIC- AIAC), the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA), the American College of Cardiology (ACC), and the American Heart Association (AHA). He is a fellow of the Heart Rhythm Society (FHRS) and the American College of Cardiology (FACC), and is an honorary member of the Korean Society of Cardiology.</p>

Is Open Scheduling

Off

Beatrice Y. Wong

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b4012680-c3c5-11eb-9ea2-7374238588d1.jpg

First Name

Beatrice

Last Name

Wong

NPI

1033656541

Faculty ID

16257

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

95560

Visit Type ID

2499

Is Open Scheduling

On

Yaron Tomer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e3b1f380-8c61-11ed-9474-c3e3b839843d.jpg

First Name

Yaron

Last Name

Tomer

NPI

1982662334

Faculty ID

14884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Yaron Tomer is the Marilyn and Stanley M. Katz Dean at Albert Einstein College of Medicine and Chief Academic Officer at Montefiore Medicine.</p>
<p>He received his M.D. degree magna cum laude from the Sackler School of Medicine of Tel Aviv University and trained in Internal Medicine at Sheba Medical Center, Israel, and in Endocrinology at the Icahn School of Medicine at Mount Sinai in New York. Prior to joining Montefiore Einstein in March 2016, he was Chief of the Division of Endocrinology, Diabetes, and Bone Disease at Mount Sinai.</p>
<p>Dr. Tomer has served on the editorial boards of <em>Endocrinology </em>and <em>The Journal of Clinical Endocrinology and Metabolism</em>, among others. He is a member of the American Society for Clinical Investigation and a Fellow of the American College of Physicians. Dr. Tomer is the recipient of several prestigious awards, including the American Thyroid Association&rsquo;s Sidney H. Ingbar Distinguished Lectureship Award, as well as its Van Meter Award.</p>
<h3>Research</h3>
<p>Dr. Tomer&rsquo;s research program focuses on the immunogenetic, epigenetic, and environmental mechanisms underlying thyroid autoimmunity, and type 1 diabetes, and on targeting these mechanisms in order to develop novel therapies. His group made several discoveries including identifying new genes and mechanisms underlying the strong association between type 1 diabetes and autoimmune thyroiditis; demonstrating that CD40 and thyroglobulin are major susceptibility genes for thyroid autoimmunity; identifying a unique amino acid variant in the peptide binding pocket of HLA-DR that is key for the development of thyroid autoimmunity; dissecting the epigenetic mechanisms by which polymorphisms in the thyroglobulin and TSHR genes interact with environmental agents (e.g. viruses) to trigger thyroid autoimmunity; and identifying a novel small molecule that can block antigen presentation in autoimmune thyroiditis.</p>
<h3>Current Projects</h3>
<ol role="list">
<li><strong>Genetic and epigenetic studies in thyroid autoimmunity</strong><br />The Tomer lab mapped several susceptibility genes for autoimmune thyroid diseases (AITD) including CD40, thyroglobulin, and TSHR. Recent data suggest that variants in regulatory regions of some of these genes interact epigenetically with environmental factors (e.g., viral infections) to trigger disease. Current studies are using epigenomic screening, including whole genome methylation studies and ChiP-seq analyses to study these genetic-epigenetic interactions.</li>
<li><strong>Epigenetic studies in type 1 diabetes</strong><br />Similar studies are utilizing epigenomic screening to analyze epigenetic interactions between known type 1 diabetes susceptibility genes and interferon alpha, a key cytokine secreted during viral infections.</li>
<li><strong>Translational studies in autoimmune thyroiditis (AITD) and type 1 diabetes</strong><br />The Tomer lab discovered that the presence of arginine at position beta-74 of the peptide binding pocket of HLA-DR is critical for the development of AITD. This discovery led to a translational project aimed at blocking thyroid antigen presentation to T-cells by the arginine beta-74 HLA-DR peptide binding pocket as a potential therapy for AITD. Recently, the Tomer lab identified a small molecule, Cepharanthine, that can block antigen presentation and suppress AITD in mouse models. Similar studies are performed in type 1 diabetes where the aim is to block the HLA-DQ8 peptide binding pocket from presenting insulin peptides to T-cells as a novel strategy to treat autoimmune diabetes.</li>
<li><strong>Genetic and functional analyses of autoimmune polyglandular syndrome (APS) type 3</strong><br />The co-occurrence of type 1 diabetes and autoimmune thyroiditis in the same individual is considered a variant of the APS type 3 syndrome. The Tomer lab discovered several new susceptibility genes for APS3. The lab is now analyzing the mechanisms by which these genes predispose to disease.</li>
<li><strong>The role of viruses in triggering autoimmune thyroiditis and type 1 diabetes</strong><br />Certain infections, such as hepatitis C, are associated with autoimmune thyroiditis and diabetes. Current studies are aimed at dissecting the mechanisms by which interferon alpha, the primary cytokine secreted during viral infections, can trigger autoimmune thyroiditis and diabetes in genetically susceptible individuals.</li>
</ol>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol role="list">
<li>Menconi F, Monti MC, Greenberg DA, Oashi T, Osman R, Davies TF, Ban Y, Jacobson EM, Concepcion ES, Li CW, <span class="underline">Tomer Y</span>. Molecular amino acid signatures in the MHC class II peptide binding pocket predispose to autoimmune thyroiditis in humans and in mice. Proc Natl Acad Sci USA 2008; 105: 14034-14039.</li>
<li>Jacobson EM, Yang H, Menconi F, Wang R, Osman R, Skrabanek L, Li CW, Fadlalla M, Gandhi A, Chaturvedi V, Smith EP, Schwemberger S, Osterburg A, Babcock GF, <span class="underline">Tomer Y</span>. Employing a recombinant HLA-DR3 expression system to dissect MHC II-thyroglobulin peptide dynamism: A genetic, biochemical, and reverse immunological perspective. J Biol Chem 2009; 284: 34231-34243.</li>
<li>Villano MJ, Huber AK, Greenberg DA, Golden BK, Concepcion E, <span class="underline">Tomer Y</span>. Autoimmune thyroiditis and diabetes: Dissecting the joint genetic susceptibility in a large cohort of multiplex families. J Clin Endocrinol Metab 2009; 94: 1458-1466.</li>
<li>Menconi F, Osman R, Monti MC, Greenberg DA, Concepcion ES, <strong>Tomer Y</strong>. Shared molecular amino acid signature in the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and thyroiditis. Proc Natl Acad Sci USA 2010; 107: 16899-16903.</li>
<li>Menconi F, Huber A, Osman R, Concepcion E, Jacobson EM, Stefan M, David, CS, <span class="underline">Tomer Y</span>. Tg.2098 is a major human thyroglobulin T-cell epitope. J Autoimmun 2010; 35: 45-51.</li>
<li>Stefan M, Jacobson EM, Huber AK, Greenberg DA, Li CW, Skrabanek L, Concepcion E, Fadlalla M, Ho K, <span class="underline">Tomer Y</span>. Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J Biol Chem 2011; 286: 31168-31179.</li>
<li>Huber AK, Finkelman FD, Li CW, Concepcion E, Smith E, Jacobson E, Latif R, Keddache M, Zhang W, <span class="underline">Tomer Y</span>. Genetically driven target tissue overexpression of CD40: A novel mechanism in autoimmune disease. J Immunol 2012; 189: 3043-3053.</li>
<li>Stefan M, Wei C, Lombardi A, Li CW, Concepcion ES, Inabnet WB 3rd, Owen R, Zhang W, <span class="underline">Tomer Y</span>. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci USA 2014; 111: 12562-12567.</li>
<li><span class="underline">Tomer Y</span>, Dolan LM, Kahaly G, Divers J, D&rsquo;Agostino Jr. RB, Imperatore G, Dabelea D, Marcovina S, Black MH, Pihoker C, Hasham A, Hammerstad SS, Greenberg DA, Lotay V, Zhang W, Monti MC, Matheis N. Genome wide identification of new genes and pathways in patients with autoimmune thyroiditis and type 1 diabetes. J Autoimmun 2015; 60: 32-39.</li>
<li>Li CW, Menconi F, Osman R, Mezei M, Jacobson EM, Concepcion E, David CS, Kastrinsky DB, Ohlmeyer M, <strong>Tomer Y</strong>. Identifying a small molecule blocking antigen presentation in autoimmune thyroiditis. J Biol Chem 2016; 291: 4079-4090.</li>
<li>Li CW, Osman R, Menconi F, Concepcion ES, <span class="underline">Tomer Y</span>. Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes. J Autoimmun 2017; 76: 1-9.</li>
<li>Faustino LC, Lombardi A, Madrigal-Matute J, Owen RP, Libutti SK, <span class="underline">Tomer Y</span>. Interferon alpha triggers autoimmune thyroid diseases via lysosomal-dependent degradation of thyroglobulin. J Clin Endocrinol Metab 2018; 103: 3678-3687.</li>
<li>Stefan-Lifshitz, M, Karakose E, Cui L, Ettela A, Yi Z, Zhang W, <span class="underline">Tomer Y</span>. Epigenetic modulation of &beta;-cells by interferon-&alpha; via PNPT1-miR26a-TET2 triggers autoimmune diabetes. JCI Insight 2019; 4: e126663.</li>
<li>Li CW, Osman R, Menconi F, Concepcion E, <span class="underline">Tomer Y</span>. Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: Therapeutic implications to Graves&rsquo; disease. J Autoimmun 2020; 108: 102402.</li>
<li>Lombardi, A, Concepcion E, Hou H, Arib H, Mezei M, Osman R, <span class="underline">Tomer Y</span>. Retro-inverso D-peptides as a novel targeted immunotherapy for type 1 diabetes. J Autoimmune 2020; 115: 102543.</li>
<li>Li CW, Sachidanandam R, Jayaprakash A, Yi Z, Zhang W, Stefan-Lifshitz M, Concepcion E, <span class="underline">Tomer Y</span>. Identification of new rare variants associated with familial autoimmune thyroid diseases by deep sequencing of linked loci. J Clin Endocrinol Metab 2021; 12: 691781.</li>
<li>Ye J, Stefan-Lifshitz M, <span class="underline">Tomer Y</span>. Genetic and environmental factors regulate the type 1 diabetes gene CTSH via differential DNA methylation. J Biol Chem 2021; 296: 100774.</li>
<li>Li CW, Osman R, Menconi F, Faustino LC, Kim K, Clarke OB, Hou H, <span class="underline">Tomer Y</span>. Cepharanthine blocks presentation of thyroid and islet peptides in a novel humanized autoimmune diabetes and thyroiditis mouse model. Front Immunol 2021; 12: 796552.</li>
</ol>

EMR ID

81697

Is Open Scheduling

Off

Vafa Tabatabaie

https://assets.montefioreeinstein.org/profiles/images/Tabatabaie_Vafa_MD_2x.jpg

First Name

Vafa

Last Name

Tabatabaie

NPI

1861789976

Faculty ID

13732

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Vafa Tabatabaie received her medical degree from Shahid Beheshti Medical University in Tehran, Iran. After several years of research on thyroid cancer in Toronto, Canada, she came to Montefiore in 2007, initially as a clinical observer and then as a researcher in the Division of Endocrinology under the direction of Drs. Norman Fleischer and Martin Surks. She graduated from the Internal Medicine Residency Program in 2011, during which her enthusiasm and teaching skills were recognized with the Award for Outstanding House Officer in Internal Medicine. She then completed her Endocrinology Fellowship in 2013 and joined the Einstein Montefiore Division of Endocrinology faculty later that year.</p>
<p>Dr. Tabatabaie is the Clinical Director for Division of Endocrinology.&nbsp;She is also the Director of Fracture Liaison Services, a multi-disciplinary team of Endocrinologist, Geriatricians and Orthopedic Surgeons focused on secondary prevention of osteoporotic fractures. &nbsp;Dr Tabatabaie is one of the founding members of Transgender Interest Group at Montefiore/Einstein. Her clinical research interests include endocrine issues in the elderly, especially metabolic bone disease and osteoporosis, as well as thyroid cancer. She has contributed to the field of endocrinology by writing journal articles, presenting posters at national endocrine meetings, and mentoring medical students, residents and fellows. In recognition of her contributions to medical education, she was accepted into Leo M Davidoff Society in 2019. She also received Department of Medicine's Humanism Award in 2018.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong>Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort</strong></p>
<p>Cancers,&nbsp;<span style="caret-color: #5b616b; color: #5b616b; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">2021 Mar 23;13(6):1464</span></p>
<p>&nbsp;</p>
<p><strong>Are We Responding Effectively to Bone Mineral Density Loss and Fracture Risk in People with Epilepsy?</strong></p>
<p>Epilepsia Open, 2020 Apr 14;5(2): 240-247</p>
<p>&nbsp;</p>
<p><strong>Changes in Bone Mineral Density During 5 Years of Adjuvant Treatment in Premenopausal Breast Cancer Patients</strong></p>
<p>Breast Cancer Research and Treatment, 2020 Feb 19</p>
<p>&nbsp;</p>
<p><strong>Treatment of Diabetic Ketoacidosis and The Weekend Effect at an Urban Tertiary-Care Center</strong></p>
<p>Endocrine Practice,&nbsp;<span style="caret-color: #5b616b; color: #5b616b; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">2020 Jun 2;26(6):634-641</span></p>
<p>&nbsp;</p>
<p><strong>Thyroid Storm Presenting as Psychosis</strong></p>
<p>Journal of Investigative Medicine High Impact Case Reports, May 2018</p>
<p>&nbsp;</p>
<p><strong>Medical Optimization of Lumbar Fusion in the Osteoporotic Patient</strong></p>
<p>Archives of Osteoporosis, 2018 March 14: 13 (1): 26</p>
<p>&nbsp;</p>
<p><strong>Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels</strong></p>
<p>Journal Of Clinical Endocrinology and Metabolism. 2016 Aug; 101 (8): 3096-104</p>
<p>&nbsp;</p>
<p><strong>Effects of Testosterone Treatment in Older Men</strong></p>
<p>New England Journal of Medicine, 2016 Feb 18: 374 (7): 611-24</p>
<p>&nbsp;</p>
<p><strong>Recruitment and Screening for the Testosterone Trials</strong></p>
<p>The Journals of Gerontology, 2015 Sep, 70(9): 1105-11</p>
<p>&nbsp;</p>
<p><strong>Association of Sex Hormones with Sexual Function, Vitality, and Physical Function of Symptomatic Older Men with Low Testosterone Levels at Baseline in the Testosterone Trials</strong></p>
<p>Journal of Clinical Endocrinology and Metabolism, 2015 Mar, 100(3):1146-55</p>
<p>&nbsp;</p>
<p><strong>Exceptional Longevity is Associated with Decreased Reproduction</strong></p>
<p>Aging, 2011 Dec, 3(12):1202-5</p>
<p>&nbsp;</p>
<p><strong>Influence of Age and Primary Tumor Size on the Risk for Residual/Recurrent Well-Differentiated Thyroid Carcinoma</strong></p>
<p>Head and Neck, 2009 Jun; 31(6):782-8</p>
<p>&nbsp;</p>
<p><strong>Post-Challenge Hyperglycemia in Older Adults is Associated with Increased Cardiovascular Risk Profile</strong></p>
<p>Journal of Clinical Endocrinology and Metabolism, 2009 May, 94(5):1595-601</p>
<p>&nbsp;</p>
<p><strong>Prognostic Value of Postsurgical Stimulated Thyroglobulin Levels after Initial Radioactive Iodine Therapy in Well-Differentiated Thyroid Carcinoma</strong></p>
<p>Head and Neck, 2008 Jun; 30(6):693-700</p>

EMR ID

5083

Biography

<p>Dr. Vafa Tabatabaie received her medical degree from Shahid Beheshti University of Medical Sciences in Tehran, Iran. After several years of research on thyroid cancer in Toronto, Canada, she came to Montefiore in 2007 as a researcher in the Division of Endocrinology under the direction of Drs. Norman Fleischer and Martin Surks. She graduated from the Internal Medicine Residency Program in 2011, during which her enthusiasm and teaching skills were recognized with the Award for Outstanding House Officer in Internal Medicine, and she completed the Endocrinology Fellowship Program in 2013. She joined the Einstein Montefiore Division of Endocrinology faculty later that year.</p><p>Dr. Tabatabaie is Director of the Fracture Liaison Service at Montefiore Medical Center. Her clinical research interests include endocrine issues in the elderly, especially metabolic bone disease and osteoporosis, as well as thyroid cancer.</p>

Visit Type ID

2499

Is Open Scheduling

On

Martin I. Surks

https://assets.montefioreeinstein.org/profiles/images/physphoto/Surks_Martin_I_MD_2835.jpg

First Name

Martin

Last Name

Surks

NPI

1891885794

Faculty ID

4372

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Current Activities:</strong>&nbsp;</p>
<ul>
<li>Program Director, Division of Endocrinology and Metabolism, Albert Einstein College of Medicine</li>
<li>Director of the Endocrinology Clinic, Montefiore Medical Center</li>
<li>Consultant in thyroid disease and general endocrinology</li>
<li>Research Mentor</li>
</ul>
<p>&nbsp;<strong>Clinical Practice:</strong></p>
<p>Dr. Surks restricts his consultative practice to disorders of the thyroid gland, and to other disorders of general endocrinology such as diseases of the pituitary, parathyroid glands, gonads, adrenal glands, and to metabolic bone disease.</p>
<p>&nbsp;<strong>Research Interests:</strong></p>
<p>Historical Summary:&nbsp;Major contributions from thyroid research at Montefiore Medical Center began nearly 100 years ago with findings of Dr. David Marine, Chairman of Pathology, that deficiency of iodine was associated with development of goiter and iodine deficiency diseases that affected hundreds of millions of people around the world His studies initiated iodine supplementation to salt in the US, and elimination of this major health problem. A Medical Physics laboratory, the progenitor of Nuclear Medicine Departments, was established in 1945 and was widely known for the earliest studies of radioactive iodine use to treat hyperthyroidism and thyroid cancer. From 1960 to 1976, Dr. Jack Oppenheimer published widely on thyroid hormone measurements and metabolism, discovered the nuclear receptor for thyroid hormone and studied its effects on different gene products</p>
<p>Most of Dr. Surks&rsquo; research has focused on thyroid physiology, pathophysiology and diseases. For the last five years, he has studied subclinical thyroid diseases, and the characterization of the reference range for serum TSH in human beings.&nbsp;</p>

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Surks is a thyroid disease expert with 40 years of experience in basic and clinical research, education and patient care. In addition to thyroid disorders, his clinical practice focuses on conditions of the pituitary, parathyroid and adrenal glands and on metabolic bone disease. His recent research has involved subclinical thyroid diseases and determining a reference range for TSH (thyroid-stimulating hormone) levels in people.&nbsp;</p>
<p>A noted educator, Dr. Surks led a collaborative project that culminated in a generic &ldquo;gold standard&rdquo; curriculum for endocrinology training programs that is used nationwide. He is author of <em>The Thyroid Book</em> and editor of the <em>Atlas of Clinical Endocrinology Volume I: Thyroid Diseases</em>. He has served on the editorial boards of several journals, including <em>Endocrinology</em> and the<em> Journal of Clinical Endocrinology &amp; Metabolism</em>, and currently is on the editorial board of <em>Thyroid</em>.&nbsp;</p>
<p>Dr. Surks is a member of the American Society for Clinical Investigation and the Association of American Physicians. He is a former president of the American Thyroid Association and the Association of Program Directors in Endocrinology, Diabetes and Metabolism. His awards include the American Thyroid Association&rsquo;s Distinguished Service Award and the Van Meter Award, and the Sidney H. Ingbar Distinguished Service Award of the Endocrine Society. He was also awarded a Mastership by the American College of Physicians in recognition of his contributions to research, education, and teaching.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol type="1">
<li>Cases, J.A., Wenig, B.M., Silver, C.E., Surks, M.I. Recurrent acute suppurative thyroiditis in an adult due to a pyriform-sinus (4th branchial pouch) fistula. J Clin Endocrinol &amp; Metab 85:953-956, 2000.</li>
<li>Cases, J.A., Surks, M.I. Changing role of scintigraphy in the evaluation of thyroid nodules; Seminars in Nuclear Medicine, Volume 30:81-87, 2000.</li>
<li>Surks, M.I., &lsquo;Hyperthyroidism&rsquo;; &lsquo;Hypothyroidism&rsquo;; &lsquo;Goiter&rsquo;; &lsquo;Iodine&rsquo;;;Thyroid Disorders&rsquo;; &lsquo;Thyroid Function Tests&rsquo;; in Encyclopedia of Public Health; Editor-in-Chief, Breslow, L., McMillan Reference USA, New York, 2002</li>
<li>Surks, M.I., Hyperthyroidism, Conn&rsquo;s Current Therapy, 2003 Eds Rakel and Bope; Elsevier Science (USA) 717-720.</li>
<li>Dubenko, M., Breining, W., Surks, M.I. &nbsp; Sclerosing lymphocytic lobulitis of the breast &nbsp; in a patient with Graves&rsquo; disease. &nbsp;2003 &nbsp;THYROID 13:309-311.</li>
<li>Rizza RA, Vigersky RA, Rodbard HW, Ladenson PW, Young WF Jr, Surks MI, Kahn R, Hogan PF. 2003. A model to determine workforce needs for endocrinologists in the United &nbsp;States until 2020. J Clin Endocrinol Metab 88: 1979-1987.</li>
<li>Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. &nbsp;Subclinical thyroid disease: Scientific Review and Guidelines for Diagnosis and Management. JAMA, 2004; 291: 228-238.&nbsp;</li>
<li>Col, NF, Surks MI. and Daniels GH: Subclinical thyroid disease: Clinical Applications. &nbsp; JAMA &nbsp;2004; 291: 239 &ndash; 243.</li>
<li>Senzel L, Surks MI, and Buettner C: Polyuria and abdominal pain in a &nbsp; young &nbsp; Jamaican woman. Laboratory Medicine, 2004; 35: 100 &ndash; 103.</li>
<li>Surks MI: Response: to &lsquo;Subclinical Thyroid Dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association and The Endocrine Society&rsquo; THYROID, 2005,15:32-33. &nbsp; &nbsp; &nbsp;&nbsp;</li>
<li>Surks MI: COMMENTARY: Subclinical Thyroid dysfunction: A joint statement on Management from the American Association of Clinical Endocrinologists, the American &nbsp;Thyroid &nbsp; &nbsp;Association, and The Endocrine society. J Clin Endocrinol Metab 2005, 90: 586-. 588</li>
<li>Surks, MI, Goswami G, Daniels GH: &nbsp;CONTROVERSY IN CLINICAL &nbsp;ENDOCRINOLOGY: The thyrotropin reference range should remain unchanged. J ClinEndcrinol Metab 2005; 5489 &ndash; 5496.</li>
<li>Surks, MI &nbsp;Hypothyroidism: New issues and controversies. The Endocrinologist. 2006.16: 203-208.</li>
<li>Meyerovitch J, Rotman-Pikiely P, Sherf M, Battat E, Levy Y, Surks MI: Serum &nbsp; &nbsp;thyrotropin (TSH) measurements in the community: 5-year follow-up in a large network of primary care physicians. Archives Internal Med &nbsp; 2007; 167: 1533 &ndash; 1538</li>
<li>Surks MI, Hollowell JG. &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol &amp; Metab &nbsp;2007; 92: 4575-4582</li>
<li>Surks MI, Hollowell JG: &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States Population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol and Metab 2007; 92: 4575-4582.</li>
<li>Surks, MI. 2008. Should the upper limit of the normal reference range for TSH be lowered? Nature Clinical Practice: Endocrinology and Metabolism 4: 370-371</li>
<li>Surks MI &nbsp;2008 Concise Review: TSH reference limits: Emerging concepts and implications for the prevalence of subclinical hypothyroidism. Clin Thyroidology 20:4-5.</li>
<li>Atzmon G, Barzilai N, Hollowell JG, Surks MI, Gabriely I: 2009 Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab 94:1251-1254.</li>
<li>Atzmon G, Barzilai N, Surks MI, Gabriely I &nbsp;2009 &nbsp; Genetic Predisposition to Elevated &nbsp;Serum Thyrotropin is Associated with Exceptional Longevity. J Clin Endocrinol Metab &nbsp;94: 4768-4775</li>
<li>Surks MI &nbsp; &nbsp;2011 &nbsp; Milestones in Thyroid Research at Montefiore Medical Center: 1920 &ndash; 2011: History and Personal Reflections--in press</li>
<li>Cases, J.A., Wenig, B.M., Silver, C.E., Surks, M.I. Recurrent acute suppurative thyroiditis in an adult due to a pyriform-sinus (4th branchial pouch) fistula. J Clin Endocrinol &amp; Metab 85:953-956, 2000.</li>
<li>Cases, J.A., Surks, M.I. Changing role of scintigraphy in the evaluation of thyroid nodules; Seminars in Nuclear Medicine, Volume 30:81-87, 2000.</li>
<li>Surks, M.I., &lsquo;Hyperthyroidism&rsquo;; &lsquo;Hypothyroidism&rsquo;; &lsquo;Goiter&rsquo;; &lsquo;Iodine&rsquo;;;Thyroid Disorders&rsquo;; &lsquo;Thyroid Function Tests&rsquo;; in Encyclopedia of Public Health; Editor-in-Chief, Breslow, L., McMillan Reference USA, New York, 2002</li>
<li>Surks, M.I., Hyperthyroidism, Conn&rsquo;s Current Therapy, 2003 Eds Rakel and Bope; Elsevier Science (USA) 717-720.</li>
<li>Dubenko, M., Breining, W., Surks, M.I. &nbsp; Sclerosing lymphocytic lobulitis of the breast &nbsp; in a patient with Graves&rsquo; disease. &nbsp;2003 &nbsp;THYROID 13:309-311.</li>
<li>Rizza RA, Vigersky RA, Rodbard HW, Ladenson PW, Young WF Jr, Surks MI, Kahn R, Hogan PF. 2003. A model to determine workforce needs for endocrinologists in the United &nbsp;States until 2020. J Clin Endocrinol Metab 88: 1979-1987.</li>
<li>Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. &nbsp;Subclinical thyroid disease: Scientific Review and Guidelines for Diagnosis and Management. JAMA, 2004; 291: 228-238.&nbsp;</li>
<li>Col, NF, Surks MI. and Daniels GH: Subclinical thyroid disease: Clinical Applications. &nbsp; JAMA &nbsp;2004; 291: 239 &ndash; 243.</li>
<li>Senzel L, Surks MI, and Buettner C: Polyuria and abdominal pain in a &nbsp; young &nbsp; Jamaican woman. Laboratory Medicine, 2004; 35: 100 &ndash; 103.</li>
<li>Surks MI: Response: to &lsquo;Subclinical Thyroid Dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association and The Endocrine Society&rsquo; THYROID, 2005,15:32-33. &nbsp; &nbsp; &nbsp;&nbsp;</li>
<li>Surks MI: COMMENTARY: Subclinical Thyroid dysfunction: A joint statement on Management from the American Association of Clinical Endocrinologists, the American &nbsp;Thyroid &nbsp; &nbsp;Association, and The Endocrine society. J Clin Endocrinol Metab 2005, 90: 586-. 588</li>
<li>Surks, MI, Goswami G, Daniels GH: &nbsp;CONTROVERSY IN CLINICAL &nbsp;ENDOCRINOLOGY: The thyrotropin reference range should remain unchanged. J ClinEndcrinol Metab 2005; 5489 &ndash; 5496.</li>
<li>Surks, MI &nbsp;Hypothyroidism: New issues and controversies. The Endocrinologist. 2006.16: 203-208.</li>
<li>Meyerovitch J, Rotman-Pikiely P, Sherf M, Battat E, Levy Y, Surks MI: Serum &nbsp; &nbsp;thyrotropin (TSH) measurements in the community: 5-year follow-up in a large network of primary care physicians. Archives Internal Med &nbsp; 2007; 167: 1533 &ndash; 1538</li>
<li>Surks MI, Hollowell JG. &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol &amp; Metab &nbsp;2007; 92: 4575-4582</li>
<li>Surks MI, Hollowell JG: &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States Population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol and Metab 2007; 92: 4575-4582.</li>
<li>Surks, MI. 2008. Should the upper limit of the normal reference range for TSH be lowered? Nature Clinical Practice: Endocrinology and Metabolism 4: 370-371</li>
<li>Surks MI. 2008 Editorial: New evidence against lowering the thyrotropin reference limits. Clin Thyroidology 20: 8</li>
<li>Surks MI &nbsp;2008 Concise Review: TSH reference limits: Emerging concepts and implications for the prevalence of subclinical hypothyroidism. Clin Thyroidology 20:4-5.</li>
<li>Atzmon G, Barzilai N, Hollowell JG, Surks MI, Gabriely I: 2009 Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab 94:1251-1254.</li>
<li>Atzmon G, Barzilai N, Surks MI, Gabriely I &nbsp;2009 &nbsp; Genetic Predisposition to Elevated &nbsp;Serum Thyrotropin is Associated with Exceptional Longevity. J Clin Endocrinol Metab &nbsp;94: 4768-4775</li>
<li>Surks MI &nbsp; &nbsp;2011 &nbsp; Milestones in Thyroid Research at Montefiore Medical Center: 1920 &ndash; 2011: History and Personal Reflections--in press</li>
</ol>

EMR ID

3515

Biography

<p>Martin I. Surks, MD, MACP, is an attending physician, Professor, Medicine, Pathology and Laboratory Medicine and Program Director Emeritus, Endocrines Clinic (1976-2018) at Montefiore Einstein. Dr. Surks&rsquo; clinical practice focuses on disorders of the thyroid gland and other disorders of general endocrinology such as diseases of the pituitary, parathyroid glands, gonads and adrenal glands, and metabolic bone disease.</p><p>After completing his Bachelor of Arts at Columbia College in 1956, Dr. Surks pursued his medical education at New York University - Bellevue College, earning his Doctor of Medicine in 1960. He began his postdoctoral training at Montefiore and completed it at Veterans Administration Hospital in 1963. Dr. Surks then returned to Montefiore to complete a postdoctoral research fellowship in arthritis and metabolic diseases in 1964.</p><p>The majority of Dr. Surks&rsquo; research focuses on thyroid physiology, pathophysiology and diseases. Most recently, he has studied subclinical thyroid diseases and the characterization of the reference range for serum TSH in human beings. He has shared his research in major peer-reviewed journals, and through editorials, abstracts, books and letters, having published more than 200 peer-reviewed papers and 2 books. He has also served on the editorial boards of several medical journals including <em>Endocrine Research, Thyroid</em> and the <em>Journal of Clinical Endocrinology and Metabolism</em>.</p><p>Dr. Surks is a Master of the American College of Physicians, a Diplomate of the National Board of Medical Examiners and a member of the American Association of Clinical Endocrinologists. He is past President of the American Thyroid Association and the Association of Program Directors of Endocrinology and Metabolism. Dr. Surks has earned many accolades throughout his career, including the Distinguished Service Award from the American Thyroid Association, the Sidney H. Ingbar Distinguished Service Award from the Endocrine Society and the Physician Recognition Award from the American Medical Association.</p>

Is Open Scheduling

On

Simona Stefan

https://assets.montefioreeinstein.org/profiles/images/physphoto/Stefan_Simona_MD_LC_420x504.jpg

First Name

Simona

Last Name

Stefan

NPI

1932524915

Faculty ID

16368

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

114470

Visit Type ID

2499

Is Open Scheduling

On

Zocdoc Link